ITGAV and neoplasm: Specifically, ligand–receptor pairs, such as IL17A-(IL17RA+IL17RC) (Figure 7A), IL17F-(IL17RA+IL17RC) (Figure 7B), IL17AF-(IL17RA+IL17RC) (Figure 7C), IFNG-(IFNGR1+IFNGR2) (Figure 7D), VEGFA-VEGFR1 (Figure 7E), POSTN-(ITGAV+ITGB5) (Figure 7F), TNFSF12-TNFRSF12A (Figure 8A), and GZMA-F2R (Figure 8B), were identified, suggesting that tumor cells with different lactate secretions may modulate immunocytes through these pairs.